Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 8 cyclopia sequence 6 Prostatic Neoplasms 3 Lung Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Urinary Bladder Neoplasms 2 Polycystic Ovary Syndrome 2 Pancreatic Neoplasms 2 Neoplasms, Plasma Cell 2 Neoplasms 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Hematologic Diseases 2 Head and Neck Neoplasms 2 Fatigue 2 Warts 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostatic Intraepithelial Neoplasia 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Papilloma 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Non-Muscle Invasive Bladder Neoplasms 1 Neuromyelitis Optica 1 Myelitis, Transverse 1 Myelitis 1 Melanoma 1

Interventions

Ipilimumab 106 Nivolumab 101 pembrolizumab 90 aldesleukin 72 Cyclophosphamide 46 Interleukin-2 45 Temozolomide 36 Dacarbazine 32 trametinib 31 dabrafenib 30 fludarabine phosphate 29 incomplete Freund's adjuvant 27 Bevacizumab 26 sargramostim 25 Vemurafenib 25 fludarabine 22 binimetinib 21 Radiosurgery 21 Paclitaxel 20 encorafenib 19 Carboplatin 19 CTLA-4 Antigen 18 cobimetinib 16 atezolizumab 15 Radiotherapy 14 Biopsy 14 Sorafenib 13 MART-1 Antigen 12 talimogene laherparepvec 11 montanide ISA 51 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Melanoma × Sugars × Clear all

NCT04899921 2024-03-26

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

Dana-Farber Cancer Institute

Phase 2 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡